Indian pharmaceutical exporter to Tunisia
Tunisia's pharmaceutical procurement runs through a structure that does not exist in most of Africa. The Pharmacie Centrale de Tunisie operates a public-sector institutional import monopoly, which means molecules above a certain annual threshold move through PCT tender awards rather than free private import. M Care Exports works with Tunisian licensed importers and PCT tender consultants to prepare DPM-compliant French CTD files, build the response packs PCT scoring committees expect, and route EUR-denominated shipments through Port de Rades with the document discipline that lets settlement clear despite the Dinar's partial-convertibility friction. The market is functional. It just requires a supplier who already knows how it actually works.
DPM registration, AMC issuance, and the WHO Collaborating Centre framework
The Direction de la Pharmacie et du Medicament, under the Tunisian Ministry of Health, issues the Authorisation de Mise sur le Marche, which is the marketing authorisation a foreign-manufactured medicine needs before commercialisation. DPM has held WHO Collaborating Centre status since 1998, which gives its review templates an EU-pharmacopoeia alignment unusual in the broader Maghreb. CTD files are accepted in French, and EU dossiers are accepted with a French-language summary attached, which simplifies preparation when the manufacturer already holds an EU registration.
AMC issuance typically runs nine to fifteen months from a complete dossier filing. The DPM review covers chemistry, manufacturing, and controls evidence, comparative bioavailability or bioequivalence data where applicable, and a clinical-overview module aligned to Tunisian therapeutic-area conventions. We prepare the dossier in regulatory French rather than commercial French, with cross-references to the Indian manufacturer's site master file and the EDQM, MHRA, USFDA, or PIC/S inspection record that supports the GMP claim.
Beyond AMC issuance, the institutional supply route is shaped by PCT. Once a molecule's annual import value crosses approximately one million US dollars in aggregated public-sector demand, PCT places it on the central tender list and the molecule moves out of free private import. That mechanism is the single most important regulatory-commercial fact about the Tunisian market. A foreign exporter who treats Tunisia as a private-import play rather than a tender-readiness play will not see institutional volume.
Tunisia's banking and FX regime introduces friction that needs to be designed into the commercial structure. The Tunisian Dinar is partially convertible, which means letters of credit denominated in EUR are mandatory for trade settlement and the Tunisian importer's bank must coordinate FX repatriation against PCT or institutional payment cycles. PCT settles against awarded contracts on a ninety to one-hundred-twenty-day cycle, and we build that cash conversion into the commercial terms rather than treating it as a surprise.
Call & WhatsApp the Mumbai desk: +91 70156 05768 · info@mcareexports.com · Mon–Sat 09:30–18:30 IST
Six capability lines that fit how Tunisia actually buys
DPM dossier preparation in French CTD format
We build full Common Technical Document files in French, structured to the DPM review template that benefits from the WHO Collaborating Centre alignment. For molecules that already hold an EU marketing authorisation we prepare the abridged route with a French summary attached. For purely Indian-registered molecules we run the full module-by-module preparation, including stability data, bioequivalence references, and the GMP attestation tied to the Indian manufacturing site.
PCT tender response packs
Pharmacie Centrale de Tunisie issues central tenders for molecules above the import-value threshold, and the response packs are scored against a precise document checklist. We prepare PCT-compliant packs that include the manufacturer technical file, the Indian regulator certificate of pharmaceutical product, GMP and free-sale attestations, sample lots, batch-stability summaries, and the commercial offer aligned to the EUR-LC settlement framework PCT specifies.
Licensed-importer private-channel supply
For molecules below the PCT central-tender threshold or for private-pharmacy retail distribution, supply runs through Tunisian licensed importers under their own AMC. We support those importers with AMC dossier preparation, EUR-LC commercial documentation, lot-traceable invoicing for private-channel resale, and consolidated routing through Port de Rades that lets a smaller importer share container space across complementary molecules.
Oncology and biologics specialised supply
Tunisia's oncology demand has grown alongside expanded national-cancer-plan coverage, and PCT tenders for biosimilars in trastuzumab, rituximab, bevacizumab, and supportive-care injectables have expanded since 2022. We supply Indian-origin biosimilars from EU-GMP-aligned manufacturing sites with comparative analytical data and bioassay references that PCT scoring committees evaluate alongside the originator file in tender review.
Port de Rades freight execution
Port de Rades handles the bulk of pharmaceutical container traffic into Tunisia, with Sfax serving the southern industrial belt as a secondary option. Sea-freight transit from Mumbai runs roughly twenty to twenty-six days through the Suez routing, with transhipment through a Mediterranean hub depending on the carrier string. We pre-clear customs paperwork with the importer ahead of berthing and coordinate temperature-controlled handling for cold-chain consignments at terminal.
EUR-LC commercial structuring against FX friction
Trade-LC issuance from Tunisian commercial banks requires EUR denomination, advance import-licence registration with the Banque Centrale de Tunisie, and PCT or importer-side documentation that survives bank scrutiny. We structure the commercial paperwork end-to-end, including the EUR invoice, LC text drafted to bank standards, certificate of origin attested at Indian chamber, and the post-shipment documentation that allows the Tunisian bank to release payment without raising secondary queries.
How a container moves from our Mumbai depot to Tunisian discharge
Sea freight from Jawaharlal Nehru Port at Mumbai to Port de Rades typically runs twenty to twenty-six days through the Suez routing, with most carrier strings transhipping at Genoa, Marsaxlokk, or Algeciras. Direct calls into Tunis exist on Mediterranean feeder services, and Sfax provides a southern alternative when the Tunisian importer's distribution network is concentrated below the Sahel. We pre-clear customs paperwork with the importer ahead of berthing so the container leaves the terminal on day of discharge rather than accumulating demurrage.
Cold-chain consignments move on temperature-mapped reefer containers with dual data loggers, and for biologics under shorter stability windows we offer scheduled air freight via Mumbai-Tunis or Mumbai-Doha-Tunis with active-temperature containers. PCT-awarded biologic supply typically routes by air for the first contracted shipment to confirm cold-chain integrity, then transitions to sea reefer once the importer and the institutional end-customer have validated the supplier's temperature-control discipline.
Commercial paperwork is structured around EUR-denominated invoices, EUR letters of credit issued by Tunisian commercial banks against pre-registered import licences, and the AMC reference number for the molecule. We provide the certificate of analysis batch-by-batch, the manufacturer free-sale certificate, the certificate of origin attested by the Indian chamber, and any French-language annex the Tunisian customs file requires. PCT shipments carry an additional layer of contract-reference paperwork tying each container to the awarded tender lot.
Where Indian supply earns its tender award in Tunisia
Tunisian local manufacturing covers roughly half of national pharmaceutical consumption and dominates commodity solid orals, antihypertensives, and the broader generic backbone. An Indian exporter who chases that segment will lose to domestic price structures. Where the Indian file wins is in oncology biosimilars, biologics, second-line anti-infectives, complex generics, paediatric strengths, and specialty therapy areas where local manufacturing has neither the analytical infrastructure nor the registered file to satisfy a PCT tender.
Anti-retroviral combinations, second-line tuberculosis therapies, and the broader public-health programme molecules sit on PCT central tenders where Indian WHO-GMP files have a structural credibility advantage given India's role as the dominant global supplier in those therapy areas. Diabetes specialty lines including modern insulins and incretin therapies, transplant immunosuppressants, and oncology supportive care are the other shelf zones where Indian supply commands sustained tender consideration.
Cold-chain biologics including insulin analogues, oncology biosimilars, and specialty injectables form the highest-value segment of Indian export into Tunisia. The combination of WHO Collaborating Centre alignment at DPM, an EU-pharmacopoeia review framework, and PCT tender scoring that weights GMP credentials heavily means an Indian manufacturer with EU-GMP, MHRA, or EDQM exposure carries genuine differentiation. We focus our Tunisia book on exactly that segment because that is where institutional-supply economics work for both sides.
A Tunis-based licensed importer was preparing for a PCT central tender on a rituximab biosimilar where the institutional volume across the national cancer-plan hospitals had crossed the threshold for central procurement. The importer had a DPM-registered file, but the previous Indian supplier had been unable to produce the comparative analytical evidence PCT scoring required, and the tender deadline was nine weeks away. We mobilised the Indian manufacturer's bioassay summary, the comparative analytical pack referencing the originator profile, EU-GMP inspection evidence from the manufacturing site, and the supply-commitment document structured to PCT contract conventions. The response pack landed inside deadline. The award came through on a twelve-month contract. First-shipment cold-chain integrity was confirmed by air-freight on the initial container, and from container two we transitioned to sea-reefer routing through Port de Rades on a quarterly schedule. The settlement cycle ran on the standard PCT ninety-to-one-hundred-twenty-day window, the EUR letter of credit released cleanly, and the importer extended the working file to a second oncology biosimilar before the contract anniversary. The win was that we built the response pack to PCT format from day one rather than retrofitting a generic export file.
An Indian export desk that already understands PCT
The single biggest filter on a Tunisia-bound shipment is whether the supplier has built around PCT or has stumbled into PCT. Most Indian exporters approach Tunisia as a private-import market, send a price list and a CPP, and discover six months later that the molecule they were quoting moved to PCT central tender at the last threshold review and they have no response pack. We built our Tunisia workflow on the opposite assumption: every molecule we onboard for a Tunisian customer is screened against the PCT threshold first, the response-pack architecture is built whether or not the molecule has crossed yet, and the licensed-importer relationship is structured to switch routes if the central tender catches up.
The second piece is regulatory fluency. DPM's WHO Collaborating Centre status and EU-pharmacopoeia alignment mean a sloppy CTD file gets caught early, and PCT scoring committees weight GMP credentials heavily. We prepare the French CTD with the cross-references that DPM expects, package the Indian manufacturer's EU-GMP, EDQM, MHRA, or USFDA inspection evidence to anticipate the PCT scoring questions, and translate the bioequivalence or bioassay summaries into regulatory French rather than letting the importer commission the translation late. That preparation is what shortens the AMC review and what wins the tender award rather than just qualifying for it.
What Tunisian buyers ask before they place a Mumbai order
Is direct private import to Tunisia possible, or does everything go through Pharmacie Centrale de Tunisie?
Both routes operate, but the boundary depends on the molecule's annual import-value tier. PCT holds a public-sector institutional import monopoly, and once a molecule's aggregated annual public-sector demand crosses approximately one million US dollars, it moves to the PCT central tender list and is no longer eligible for free private institutional import. Private-channel pharmacy retail distribution remains open through Tunisian licensed importers operating under their own AMC. We screen every molecule we onboard against the threshold so the customer knows upfront whether they are quoting a PCT-route file or a private-channel file.
How long does DPM marketing authorisation take from a complete dossier filing?
Nine to fifteen months is the practical AMC issuance window once the file is administratively complete. The faster end of that range applies when the molecule already holds an EU marketing authorisation and the abridged route with a French summary is available. The slower end applies when the molecule is purely Indian-registered, when stability data needs supplementation, or when DPM raises clarifications around the manufacturing-site GMP credentials. The WHO Collaborating Centre alignment at DPM means review depth is genuine, but a well-prepared file moves through without back-and-forth iteration on procedural matters.
What is involved in preparing a PCT tender response pack?
PCT tenders publish a response checklist that covers the manufacturer technical file, the Indian regulator certificate of pharmaceutical product, GMP and free-sale attestations, batch-stability summaries, sample lots for laboratory verification, the commercial offer in EUR-LC format, and the supply-commitment document structured to PCT contract conventions. We prepare the entire pack in French, package the Indian manufacturer evidence to anticipate scoring questions, and submit through the licensed-importer or consultant relationship that PCT recognises. Lead time from tender publication to submission is typically six to ten weeks.
Does the Tunisian Dinar's partial convertibility cause settlement problems?
Settlement runs cleanly when the commercial structure is built for it. EUR-denominated letters of credit issued by Tunisian commercial banks against a pre-registered import licence with the Banque Centrale de Tunisie are the standard route. PCT-awarded supply settles on a ninety to one-hundred-twenty-day cycle from delivery acceptance, which we build into the commercial terms rather than treating as a surprise. Private-channel licensed-importer settlement runs on shorter cycles depending on the bilateral relationship. We have not had a settlement fail on a properly structured Tunisian LC.
Which Tunisian port should we route an ambient pharmaceutical container through?
Port de Rades handles the bulk of Tunisian pharmaceutical container traffic and is the default discharge point for Mumbai-origin shipments. Sfax serves as a secondary option when the importer's distribution network is concentrated in the southern Sahel or when carrier-string availability favours a southern call. We pre-clear customs paperwork with the importer before vessel arrival so the container moves to bonded warehouse on the day of discharge, which keeps demurrage exposure inside the standard free-time allowance and protects the cold chain on temperature-controlled lots.
What therapeutic areas does M Care prioritise for Tunisia versus competing with local manufacturers?
Oncology biosimilars, biologics, second-line and last-line anti-infectives, complex generics, transplant immunosuppressants, anti-retroviral and anti-tuberculosis combinations, modern insulins and incretin therapies, and paediatric scarce strengths. These are the segments where Tunisian local manufacturing has neither the analytical infrastructure nor the registered-file depth to fully cover demand, which makes them the natural shelf zones for Indian WHO-GMP supply. We deliberately stay light on commodity solid orals where Tunisian manufacturers have a structural advantage, because that is not a segment a foreign supplier wins on.
How does WHO Collaborating Centre status at DPM affect dossier preparation?
DPM has held WHO Collaborating Centre status since 1998, which means its review templates carry an EU-pharmacopoeia alignment that is unusual in the broader Maghreb. Practically, that means CTD files prepared to EU conventions translate well into the DPM format, EU marketing-authorisation evidence is given genuine weight in review, and the abridged-route option exists when the molecule already holds an EU AMC. It also raises the bar on dossier quality: a sloppy CTD file gets caught early in administrative validation rather than passing through and failing in scientific review.
Open a Tunisian working file with a desk that already knows PCT
PCT-format response packs
Tender response packs built to Pharmacie Centrale de Tunisie scoring conventions, with manufacturer evidence, sample lots, and EUR-LC commercial offers packaged inside the published response window.
DPM CTD discipline
French CTD prepared to DPM review templates that benefit from WHO Collaborating Centre alignment, with abridged-route preparation for molecules already holding an EU marketing authorisation.
EUR-LC settlement built in
Commercial paperwork structured around EUR letters of credit, pre-registered import licences with Banque Centrale de Tunisie, and PCT settlement-cycle realism so cash conversion is designed not surprised.
Top categories we ship to Tunisia
Anti-infectives
Second-line antibiotics, anti-retroviral combinations, anti-tuberculosis regimens, and antifungals supplied to Tunisian licensed importers and PCT tender awards under DPM-registered files.
Oncology biosimilars
Trastuzumab, rituximab, bevacizumab, and oncology supportive care supplied into Tunisian national-cancer-plan hospitals through PCT tender awards with EU-GMP manufacturing evidence.
Cardiovascular
Specialty cardiovascular lines including anticoagulants, heart-failure therapies, and dyslipidaemia molecules where local Tunisian manufacturing capacity is constrained or absent.
Diabetes and endocrine
Insulin analogues, incretin therapies, and endocrine specialty lines delivered through cold-chain routing into Port de Rades with full DPM-registered AMC documentation.
Respiratory
Inhalation devices, anti-asthma, and COPD therapies from EDQM- and MHRA-inspected Indian manufacturing sites, registered through DPM and supplied across institutional and private channels.
General and OTC
Selective OTC and general-prescription lines that fill specific Tunisian retail gaps where local manufacturing capacity does not extend or paediatric scarce-strength demand persists.
Services that sit underneath every Tunisia shipment
WHO-GMP compliance
Manufacturing-site GMP evidence packaged for DPM filings and PCT tender scoring, including EU-GMP, EDQM, MHRA, and USFDA inspection histories that Tunisian reviewers reference during evaluation.
Dossier preparation (CTD)
Full French-language Common Technical Document preparation aligned to DPM review templates, with abridged-route preparation for molecules already holding an EU marketing authorisation.
Cold-chain validation
Temperature-mapped reefer and active-air-freight container audits from Mumbai cold-room loading through Port de Rades discharge, with dual-logger evidence packaged for institutional acceptance testing.
Send the molecule list. We send back a PCT-versus-private read.
Share the Tunisian importer name, the molecules under consideration, and the institutional or retail channel target. Within five working days we return a PCT-threshold screen for each molecule, a DPM filing plan with French CTD timeline, a PCT response-pack architecture if the molecule has crossed the central-tender threshold, and an EUR-LC commercial structure aligned to Banque Centrale de Tunisie conventions. No upfront commitment. The plan tells you which route each molecule actually takes before any dossier work starts.
Start a Tunisia enquiry → Back to all markets